Fig. 1

MYSM1 is negatively associated with tumorigenesis in CRC. A Representative IHC of MYSM1 expression in different organs using a tissue microarray of normal (upper) and tumor (lower) tissues. Scale bars: 100 μm. B Different expression levels of MYSM1 in a series of tumor and paired normal tissues were analyzed based on the GEPIA database. The data are shown as the means ± SDs (*P < 0.05). C Representative IHC of MYSM1 expression in stage I-IV (a-f) CRC samples in the tissue microarray. Scale bars: 100 μm. D Engineered CT26 cells (control: wild-type; Mysm1 KO: Mysm1 knocked out by CRISPR-Cas9) or SW620 cells (Lenti-NC: infected with lentiviral vehicle; Lenti-MYSM1: infected with MYSM1-overexpressing lentivirus) were transplanted subcutaneously into athymic BALB/c mice. The masses and growth curves of the neoplasms are shown. The data are presented as the means ± SDs (*P < 0.05, n = 3 independent experiments). E The OS in CRC (GSE24551), breast cancer (GSE3494_U133B) and chronic lymphocytic leukemia (CLL) (GSE22762_U133P2) was analyzed with a Kaplan-Meier survival curve. MYSM1 expression data from the GEO database were divided into two groups using the median. Statistical significance was assessed via the P log-rank test